摘要
痛风为常见的炎性关节疾病。高尿酸水平引起尿酸盐结晶并沉积,导致痛风性关节炎和尿酸尿石病。非布司他为黄嘌呤氧化酶抑制药,能抑制次黄嘌呤转化为黄嘌呤以及黄嘌呤转化为尿酸,用于治疗伴痛风的高尿酸血症患者。本文综述了其作用机制、药效学、药动学和临床评价。
Gout is a common type of arthritis caused by urate crystal formation and deposition, which is due to increasing levels of hyperuricaemia. Febuxostat is a xanthine oxidase （XO） inhibitor, which could reduce serum uric acid （sUA） levels by impeding the transformation of hypoxanthine to xanthine and of xanthine to uric acid. Febuxostat is indicated for the chronic management of hyperuricemia in patients with gout. The mechanism, pharmacokinetic and clinical evaluation of febuxostat was reviewed in this paper.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2010年第8期635-638,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
非布司他
高尿酸血症
痛风
药理作用
临床评价
febuxostat
hyperuricemia
gout
pharmacologic actions
clinical evaluation
